Open AccessPrevalence of the epidermal growth factor receptor mutations in lung adenocarcinoma patients from the Middle East region
Author(s) -
Arafat Tfayli,
Ghina Fakhri,
Majd Sassine Al Assaad
Publication year - 2019
Publication title -
annals of thoracic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.639
H-Index - 33
eISSN - 1817-1737
pISSN - 1998-3557
DOI - 10.4103/atm.atm_344_18
Subject(s) - medicine , epidermal growth factor receptor , adenocarcinoma , lung , epidermal growth factor , lung cancer , oncology , cancer research , receptor , cancer
Lung cancer remains a major cause of cancer mortality with a 5-year survival in advanced stages around 4%. Platinum-based chemotherapy was routinely used as the standard of care in patients with advanced nonsmall cell lung cancer, but it is being progressively replaced by targeted molecular therapy. One of the molecular aberrations harbored by lung adenocarcinoma is the epidermal growth factor receptor (EGFR). A large ethnic variation has been reported in the prevalence of EGFR mutations in patients with lung adenocarcinoma. Data regarding its prevalence from the Middle East area remains limited. This paper aims at reviewing the data available for the prevalence of this mutation in the Middle Eastern patient population and comparing it with other reported series.